SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines into clinical development. The round was led by Vida Ventures and included participation from ARK Invest, Bayer’s Leaps by Bayer, Otsuka, UCB Ventures, and multiple strategic and life-sciences investors. The company plans to advance lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD), while expanding its pipeline of targeted redosable genetic medicines across organ systems. SonoThera’s platform combines ultrasound-mediated delivery (RIPPLE) with a payload engineering approach (PORE), designed to support larger payloads and redosing. SonoThera expects its first DMD clinical trial in 2027, positioning the financing as a bridge for clinical scaling and additional platform validation.